RIGEL PHARMACEUTICALS INC short interest in 2026
In 2026, RIGEL PHARMACEUTICALS INC's disclosed short interest ran from 20.39% of shares outstanding on 15 Jan 2026 to 17.09% on 15 Sep 2026, a change of -3.30 percentage points. The year's high was 22.71% on 15 Apr 2026 and its low 16.56% on 31 Jul 2026, averaging 19.52% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.83 days on 15 Sep 2026. Full history: RIGEL PHARMACEUTICALS INC.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 20.39% (15 Jan 2026)
- End of year
- 17.09% (15 Sep 2026)
- Change
- -3.30 pp
- High
- 22.71% (15 Apr 2026)
- Low
- 16.56% (31 Jul 2026)
- Average
- 19.52%
- Highest days to cover
- 15.83 (15 Sep 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 20.39% | 6.72 | results (8-K) |
| 30 Jan 2026 | 20.55% | 12.12 | |
| 13 Feb 2026 | 20.90% | 14.25 | |
| 27 Feb 2026 | 20.67% | 13.00 | |
| 13 Mar 2026 | 20.55% | 7.06 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 20.99% | 13.26 | |
| 15 Apr 2026 | 22.71% | 11.26 | |
| 30 Apr 2026 | 21.27% | 12.09 | |
| 15 May 2026 | 21.33% | 7.49 | 10-Q filed, results (8-K) |
| 29 May 2026 | 21.27% | 12.02 | |
| 15 Jun 2026 | 18.69% | 11.18 | |
| 30 Jun 2026 | 17.58% | 7.18 | |
| 15 Jul 2026 | 17.07% | 7.87 | |
| 31 Jul 2026 | 16.56% | 10.55 | |
| 14 Aug 2026 | 17.15% | 9.76 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 17.03% | 9.11 | |
| 15 Sep 2026 | 17.09% | 15.83 |
See also: RIGEL PHARMACEUTICALS INC's full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.